NASDAQ: APMD · Life Sciences · 3 alerts · CIK 1745648
Share price
$16.28Close, Nov 16
Market cap
$678M
Shares outstanding
41.63MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Apnimed, Inc. filings on SEC EDGAR ↗
Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on its lead product candidate, Oxnimbi, which has completed Phase 3 clinical trials. The company reports significant operating losses since inception and anticipates requiring substantial additional funding to support its commercialization efforts and regulatory approval processes.
Apnimed reported third quarter 2026 financial results, highlighting a cash position of $351.8 million following its upsized IPO in August. The company's NDA for AD109 (Oxnimbi) for the treatment of obstructive sleep apnea remains under FDA review with a PDUFA goal date of February 28, 2027.
“We are in a transformational period at Apnimed. With our NDA for AD109 (proposed proprietary name Oxnimbi) under FDA review and a PDUFA goal date of February 28, 2027, we are advancing our launch readiness while continuing to strengthen the clinical story.”
Apnimed, Inc. announced that its previously issued financial statements for the three and six months ended June 30, 2026, should no longer be relied upon due to an accounting error. The error involves the misclassification of an $85.4 million gain from the sale of its interest in Shionogi-Apnimed Sleep Science, LLC as continuing operations rather than discontinued operations. The company intends to file a restatement on Form 10-Q/A to correct the classification, which does not impact total net income, cash, or total assets.